Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

BeiGene Starts China Clinical Trial of PD-1 Candidate

publication date: Dec 30, 2016
BeiGene has dosed its first patient in a China Phase I trial of BGB-A317, a PD-1 treatment for cancer. The trial will enroll patients with solid tumors. BGB-A317 has already been administered to patients in Australia, New Zealand, the US and Taiwan. In the US, it is also being tested with another BeiGene cancer drug, BGB-3111, a small molecule BTK inhibitor in patients with B-Cell lymphoid malignancies. Located in Beijing, BeiGene has four molecularly-targeted and immuno-oncology drug candidates undergoing clinical trials in China, the US and elsewhere. More details....

Stock Symbol: (NSDQ: BGNE)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital